Cargando…

Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices

INTRODUCTION: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS(®)) is a patient-controlled analgesia system used for the management of acute postoperative pain, designed to be utilized in a hospital setting. The objective of the two studies was to determine if fentanyl ITS could be sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemke, John, Sardariani, Edmond, Phipps, Joseph Bradley, Patel, Niki, Itri, Loretta M., Caravelli, James, Viscusi, Eugene R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020125/
https://www.ncbi.nlm.nih.gov/pubmed/27423647
http://dx.doi.org/10.1007/s12325-016-0381-y
_version_ 1782453179457208320
author Lemke, John
Sardariani, Edmond
Phipps, Joseph Bradley
Patel, Niki
Itri, Loretta M.
Caravelli, James
Viscusi, Eugene R.
author_facet Lemke, John
Sardariani, Edmond
Phipps, Joseph Bradley
Patel, Niki
Itri, Loretta M.
Caravelli, James
Viscusi, Eugene R.
author_sort Lemke, John
collection PubMed
description INTRODUCTION: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS(®)) is a patient-controlled analgesia system used for the management of acute postoperative pain, designed to be utilized in a hospital setting. The objective of the two studies was to determine if fentanyl ITS could be safely used with X-rays, computerized tomography (CT) scans and radiofrequency identification (RFID) devices. METHODS: The ITS system has two components: controller and drug unit; the studies utilized ITS systems without fentanyl, referred to as the ITS Placebo system. The first study evaluated the effect of X-radiation on the operation of an ITS Placebo system. Five ITS Placebo systems were exposed to X-rays (20 and 200 mSv total radiation dose—the 200 mSv radiation dose represents a tenfold higher exposure than in clinical practice) while operating in the Ready Mode and five were exposed while operating in the Dose Mode. The second study evaluated the effect of RFID (worst-case scenario of direct contact with an RFID transmitter) on the operation of an ITS Placebo system. During these tests, observations of the user interface and measurements of output voltage confirmed proper function throughout all operational modes (Ready Mode, Dose Mode, End-of-Use Mode, and End-of-Life Mode). RESULTS: The ITS Placebo system met all specifications and no functional anomalies were observed during and following X-ray exposure at two radiation dose levels or exposure at six different combinations of RFID frequencies and field strengths. CONCLUSION: The performance of the ITS system was unaffected by X-ray exposure levels well beyond those associated with diagnostic X-rays and CT scans, and by exposure to radiofrequency field strengths typically generated by RFID devices. These results provide added confidence to clinicians that the fentanyl ITS system does not need to be removed during diagnostic X-rays and CT scans and can also be utilized in close proximity to RFID devices. FUNDING: The studies and writing of this manuscript were supported financially by The Medicines Company.
format Online
Article
Text
id pubmed-5020125
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-50201252016-09-27 Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices Lemke, John Sardariani, Edmond Phipps, Joseph Bradley Patel, Niki Itri, Loretta M. Caravelli, James Viscusi, Eugene R. Adv Ther Original Research INTRODUCTION: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS(®)) is a patient-controlled analgesia system used for the management of acute postoperative pain, designed to be utilized in a hospital setting. The objective of the two studies was to determine if fentanyl ITS could be safely used with X-rays, computerized tomography (CT) scans and radiofrequency identification (RFID) devices. METHODS: The ITS system has two components: controller and drug unit; the studies utilized ITS systems without fentanyl, referred to as the ITS Placebo system. The first study evaluated the effect of X-radiation on the operation of an ITS Placebo system. Five ITS Placebo systems were exposed to X-rays (20 and 200 mSv total radiation dose—the 200 mSv radiation dose represents a tenfold higher exposure than in clinical practice) while operating in the Ready Mode and five were exposed while operating in the Dose Mode. The second study evaluated the effect of RFID (worst-case scenario of direct contact with an RFID transmitter) on the operation of an ITS Placebo system. During these tests, observations of the user interface and measurements of output voltage confirmed proper function throughout all operational modes (Ready Mode, Dose Mode, End-of-Use Mode, and End-of-Life Mode). RESULTS: The ITS Placebo system met all specifications and no functional anomalies were observed during and following X-ray exposure at two radiation dose levels or exposure at six different combinations of RFID frequencies and field strengths. CONCLUSION: The performance of the ITS system was unaffected by X-ray exposure levels well beyond those associated with diagnostic X-rays and CT scans, and by exposure to radiofrequency field strengths typically generated by RFID devices. These results provide added confidence to clinicians that the fentanyl ITS system does not need to be removed during diagnostic X-rays and CT scans and can also be utilized in close proximity to RFID devices. FUNDING: The studies and writing of this manuscript were supported financially by The Medicines Company. Springer Healthcare 2016-07-16 2016 /pmc/articles/PMC5020125/ /pubmed/27423647 http://dx.doi.org/10.1007/s12325-016-0381-y Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Lemke, John
Sardariani, Edmond
Phipps, Joseph Bradley
Patel, Niki
Itri, Loretta M.
Caravelli, James
Viscusi, Eugene R.
Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title_full Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title_fullStr Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title_full_unstemmed Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title_short Fentanyl Iontophoretic Transdermal System (IONSYS(®)) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices
title_sort fentanyl iontophoretic transdermal system (ionsys(®)) can be safely used in the hospital environment with x-rays, computerized tomography and radiofrequency identification devices
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020125/
https://www.ncbi.nlm.nih.gov/pubmed/27423647
http://dx.doi.org/10.1007/s12325-016-0381-y
work_keys_str_mv AT lemkejohn fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT sardarianiedmond fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT phippsjosephbradley fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT patelniki fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT itrilorettam fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT caravellijames fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices
AT viscusieugener fentanyliontophoretictransdermalsystemionsyscanbesafelyusedinthehospitalenvironmentwithxrayscomputerizedtomographyandradiofrequencyidentificationdevices